Option Care Health (OPCH) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Option Care Health is set to announce its Q3 2025 earnings on Thursday, October 30th, with expectations of $0.43 per share in earnings and $1.4124 billion in revenue.
• The company's stock is currently rated as a "Moderate Buy" by analysts, with a consensus target price of $35.10.
• Recent insider transactions show increased ownership, with Director Harry M. Jansen Kraemer, Jr. acquiring 36,000 shares at $27.15 each, reflecting confidence in the company's future performance.

Option Care Health (NASDAQ:OPCH - Get Free Report) will likely be releasing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $0.43 per share and revenue of $1.4124 billion for the quarter. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS.Investors can check the company's upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Option Care Health (NASDAQ:OPCH - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.01. The company had revenue of $1.42 billion for the quarter, compared to analysts' expectations of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.Option Care Health's revenue was up 15.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.30 earnings per share. On average, analysts expect Option Care Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Option Care Health Trading Up 0.3%

Shares of NASDAQ OPCH opened at $28.29 on Thursday. Option Care Health has a twelve month low of $21.39 and a twelve month high of $35.53. The firm has a market cap of $4.59 billion, a PE ratio of 22.63, a price-to-earnings-growth ratio of 1.71 and a beta of 0.88. The business has a fifty day simple moving average of $28.01 and a two-hundred day simple moving average of $30.18. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.81.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Weiss Ratings reissued a "hold (c)" rating on shares of Option Care Health in a research report on Wednesday, October 8th. TD Cowen began coverage on shares of Option Care Health in a research note on Thursday, October 2nd. They issued a "hold" rating and a $30.00 price objective for the company. JMP Securities increased their target price on Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a research report on Thursday, July 31st. Citigroup reissued an "outperform" rating on shares of Option Care Health in a research report on Thursday, July 31st. Finally, Cowen initiated coverage on Option Care Health in a research report on Thursday, October 2nd. They set a "hold" rating on the stock. Nine equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $35.10.

Insiders Place Their Bets

In other news, Director Harry M. Jansen Kraemer, Jr. acquired 36,000 shares of the business's stock in a transaction dated Wednesday, August 20th. The shares were acquired at an average cost of $27.15 per share, with a total value of $977,400.00. Following the completion of the acquisition, the director owned 375,390 shares of the company's stock, valued at approximately $10,191,838.50. This trade represents a 10.61% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Norman L. Wright purchased 3,411 shares of the business's stock in a transaction that occurred on Tuesday, September 9th. The stock was acquired at an average price of $29.31 per share, for a total transaction of $99,976.41. Following the acquisition, the director owned 15,501 shares in the company, valued at $454,334.31. This trade represents a 28.21% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 59,411 shares of company stock valued at $1,627,576. Insiders own 0.64% of the company's stock.

Hedge Funds Weigh In On Option Care Health

A number of hedge funds have recently bought and sold shares of OPCH. McIlrath & Eck LLC acquired a new position in shares of Option Care Health during the second quarter valued at approximately $37,000. EverSource Wealth Advisors LLC boosted its stake in Option Care Health by 528.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,407 shares of the company's stock worth $46,000 after purchasing an additional 1,183 shares during the last quarter. Osaic Holdings Inc. grew its holdings in shares of Option Care Health by 149.4% during the second quarter. Osaic Holdings Inc. now owns 3,709 shares of the company's stock worth $123,000 after buying an additional 2,222 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Option Care Health in the second quarter valued at about $192,000. Finally, Empowered Funds LLC acquired a new stake in shares of Option Care Health in the first quarter valued at about $208,000. Hedge funds and other institutional investors own 98.05% of the company's stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.